GEN Exclusives

More »

GEN News Highlights

More »
Aug 16, 2007

Ardea Receives $0.5M from Valeant upon Selection of Development Candidates

  • Ardea Biosciences received its first milestone payment of $0.5 million from Valeant Pharmaceuticals. The fee was triggered by Valeant's selection of several pre-IND candidates for its potassium-channel opener program.

    In December 2006, Ardea bought certain discovery and preclinical assets from Valeant. Separately, Valeant also signed a deal to pay Ardea for research on unidentified neurological treatments.

    "Starting with a very interesting first-generation compound, we have successfully improved its metabolic and pharmacokinetic properties, while increasing potency by up to 50-fold,” says Barry D. Quart,  president and CEO of Ardea. “We are pleased to be recognized for achieving this important milestone and for its validation of our fully-integrated discovery, research, and development platform.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »